Artesunate for I njection PowerPoint Presentation

Artesunate  for  I njection PowerPoint Presentation

2019-03-02 3K 3 0 0

Description

Ipca. Rectal . artesunate. Strides . Pharma. Pyronaridine-. artesunate . granules. Shin Poong. Artemether- . lumefantrine. D. ispersible. . Novartis. Artesunate . for . I. njection . Fosun (Guilin) . ID: 754817

Embed code:

Download this presentation



DownloadNote - The PPT/PDF document "Artesunate for I njection" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Presentations text content in Artesunate for I njection

Slide1

Artesunate for Injection Ipca

Rectal

artesunate

Strides

Pharma

Pyronaridine-

artesunate

granules

Shin Poong

Artemether-

lumefantrine

Dispersible Novartis

Artesunate

for

Injection Fosun (Guilin)

Artesunate

-

mefloquine Cipla

Pyronaridine-

a

rtesunateShin Poong

Dihydr

o

artemisinin- piperaquine Alfasigma

Sulfadoxine

-

pyrimethamine+amodiaquine Fosun (Guilin)

Rectal

artesunate

Cipla

Artesunate

-

amodiaquine Sanofi

Dihydroartemisinin

-

piperaquine dispersibleAlfasigma

Sulfadoxine

-

pyrimethamine+amodiaquine dispersibleS Kant

DSM265

Takeda

MMV048

Cipargamin

Novartis

Artefenomel

/

Ferroquine

Sanofi

Ganaplacide

/

Lumefantrine

Novartis

P218

Janssen

SJ733

Kentucky/Eisai

MMV253

Zydus

Cadila

SAR121Sanofi

MMV-

supported projects

PantothenatesTropIQ/RUMC

MiniportfolioGSK

Translational

Product development

Access

Preclinical

Patient confirmatory

Approved/ERP

Human volunteers

Patient exploratory

Regulatory review

Research

Candidate profiling

Lead optim

ization

3

2

4

6

4

1

3

5

MMV support to projects may include financial, in-kind, and advisory activities.

Footnotes: Included in MMV portfolio after product approval and/or development. DND

i

and partners completed development and registration of ASMQ and ASAQ.

Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.

WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.

Paediatric formulation.

M5717

Merck

KGaA

Tafenoquine

GSK

9

MMV370

MMV371

MMV052

Tafenoquine

paediatric

GSK

7

8

Phenotypic Lead

Daiichi-Sankyo

Open Source Series

University of Sydney

Phe

tRNA

ligase

Broad Institute/

Eisai

Purines

Celgene

GWT1

Eisai

Molecular Target

DDU Dundee

Azabenzimidazole

UNICAMP

Miniportfolio

Novartis

SJ733 backup

Kentucky

Phenotypic

Lead

Sanofi

DHODH

UTSW/ UW/

Monash

Phenotypic

Lead

UCT

Intra-muscular

Calibr

Brand names 1:

Coartem

®

Dispersible

; 2:

Artesun

®

;

3:

Eurartesim

®; 4:

Pyramax

® tablets or granules;

5

: ASAQ Winthrop®; 6

: SPAQ-CO

TM

; 7: 100mg

Artesunate

Rectocaps

;

8

:

ArtecapTM ; 9: Kozenis/Krintafel (Trademarks owned or licensed by GSK)

Slide2

Target Product Profiles and Target Candidate ProfilesMMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign.Burrows JN et al., New developments in anti‑malarial target candidate and product profiles et al. Malar J (2017) 16:26 updates the previous profiles in Burrows J et al.; Malaria Journal 2013 12:187Target Product Profilesindicated by bars at the bottom of each compound box

3-day cure, artemisinin-based combination therapies

Uncomplicated malaria treatments aiming at a new single-exposure radical cure (SERC) TPP-1

Severe malaria treatment / pre-referral intervention

Intermittent /seasonal malaria chemoprevention

Products targeting prevention of relapse for P. vivax Single-exposure chemoprotection (SEC) TPP-2

Burrows Burrows

et al., 2013 et al., 2017Asexual blood stages (TCP-1,2) TCP-1Relapse prevention (TCP-3a) TCP-3Transmission reduction (TCP-3b) TCP-5,6Chemoprotection (TCP- 4) TCP-4Target Candidate Profiles activities for each individual molecule, indicated by symbols added to each compound in the translational portfolio

Footnotes: MMV-supported projects


About DocSlides
DocSlides allows users to easily upload and share presentations, PDF documents, and images.Share your documents with the world , watch,share and upload any time you want. How can you benefit from using DocSlides? DocSlides consists documents from individuals and organizations on topics ranging from technology and business to travel, health, and education. Find and search for what interests you, and learn from people and more. You can also download DocSlides to read or reference later.